Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy

HIV Medicine

Volumn 6, Issue 4, 2005, Pages 240-244

  Boccara, F ^a   Ederhy, S ^a   Janower, S ^a   Benyounes, N ^a   Odi, G ^a   Cohen, Ariel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Acute coronary syndrome; AIDS; HIV; Myocardial infarction; Protease inhibitors

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAVIRENZ; FENOFIBRATE; FIBRINOLYTIC AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY RISK; CORONARY STENT; DYSLIPIDEMIA; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LUNG EDEMA; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SMOKING; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROTEASE INHIBITORS; RECURRENCE; RISK FACTORS; SMOKING; SYNDROME; THROMBOLYTIC THERAPY;

EID: 20344379492     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00283.x     Document Type: Article

References (30)

1. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
2. Gallet B, Pulik M, Genet P et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958-1959.
3. Duong M, Buisson M, Cottin Y et al. Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review. Clin Cardiol 2001; 24: 690-694.
4. Boccara F, Teiger E, Cohen A. Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors. J Invasive Cardiol 2002; 14: 343-346.
5. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
6. Friis-Moller N, Sabin CA, Weber R et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
7. Klein D, Hurley LB, Quesenberry CPJ et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
8. Mary-Krause M, Cotte L, Simon A et al. and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
9. Holmberg SO, Moorman AC, Williamson JM et al. HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
10. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 3002; 34: 98-102.
11. Matetzky S, Domingo M, Kar S et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163: 457-460.
12. Hsue PY, Giri K, Erickson S, MacGregor JS et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004; 109: 316-319.
13. Ambrose JA, Gould RB, Kurian DC et al. Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection. Am J Cardiol 2003; 92: 301-303.
14. Doughty M, Mehta R, Bruckman D et al. Acute myocardial infarction in the young-The University of Michigan experience. Am Heart J 2002; 143: 56-62.
15. Akosah KO, Cerniglia RM, Havlik P et al. Myocardial infarction in young adults with low-density lipoprotein cholesterol levels ≤ 100 mg/dL: clinical profile and 1-year outcomes. Chest 2001; 120: 1953-1958.
16. Fournier JA, Sanchez-Gonzalez A, Quero J et al. Normal angiogram after myocardial infarction in young patients: a prospective clinical angiographic and long-term follow-up study. Int J Cardiol 1997; 60: 281-287.
17. Garoufalis S, Kouvaras G, Vitsias G et al. Comparison of angiographic findings, risk factors, and long term follow-up between young and old patients with a history of myocardial infarction. Int J Cardiol 1998; 67: 75-80.
18. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-577.
19. Moyle GJ, Buss NE, Gazzard BG. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immune Defic Syndr 2002; 30: 460-462.
20. Dube MP, Stein JH, Aberg JA et al. Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-627.
21. Wanke CA, Falutz JM, Shevitz A et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002; 34: 248-259.
22. Volberding PA, Murphy RL, Barbaro G et al. The pavia consensus statement. AIDS 2003; 17 (Suppl. 1): 170-179.
23. Carr A, Samaras K, Chisholm DJ et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881-1883.
24. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
25. Danesh J, Collins R, Peto R. Chronic infections and coronary disease: is there a link? Lancet 1997; 350: 430-436.
26. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
27. Zhong DS, Lu XH, Conklin BS et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1560-1566.
28. Schecter AD, Berman AB, Yi L et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98: 10142-10147.
29. Barbaro G, Barbarini G, Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001; 344: 1799-1800.
30. Meng Q, Lima JA, Lai H et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144: 642-648.